论文信息 - C-reactive protein and hormone replacement therapy.

C-reactive protein and hormone replacement therapy.

To the Editor: Two recent articles in Circulation 1 2 described increases in C-reactive protein (CRP) concentration with hormone replacement therapy (HRT) that consisted of oral estrogen or estrogen plus progestin preparations. The authors argued that such a proinflammatory effect of HRT may help to explain the increased risk of cardiovascular disease in the first year of treatment with HRT, as observed in the recent HERS trial (Heart and Estrogen-progestin Replacement Study). In contrast, in related research, we have found that in a double-blind trial of 33 women with type 2 diabetes, a combination of transdermal estradiol (80 μg) and continuous oral norethisterone (1 mg) significantly reduced CRP concentrations relative to placebo after 6 months of therapy.3 What could be the reasons for the discordant results observed? There were differences in design between the studies. The PEPI study1 was a 3-year randomized trial, whereas Ridker et al presented cross-sectional results from the Women’s Health Study (WHS).2 In addition, the …

N. Sattar | R. Wild | N. Forouhi

[1] C. Stehouwer,et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[2] J. Manson,et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[3] E. Barrett-Connor,et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[4] N. Sattar,et al. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes , 1999, The Lancet.

[5] C. Stehouwer,et al. Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women , 1999, Thrombosis and Haemostasis.

[6] L. Kuller,et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[7] I. Olsen,et al. IL-6 expression by oral fibroblasts is regulated by androgen. , 1998, Cytokine.

[8] C. Fletcher,et al. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. , 1996, Atherosclerosis.